9823 Capital’s Jade Biosciences JBIO Stock Holding History

9823 Capital’s Portfolio JBIO Stock Details JBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-53,191	Closed	-$821K	–	48
2025 Q4	$821K	Buy	+53,191	New	+$624K	0.57%	14

Other funds holding JBIO

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

RCP

Remedium Capital Partners Fort Lauderdale, Florida $452M AUM

9823 Capital's JBIO Position: Q1 2026 in Review

9823 Capital sold out of Jade Biosciences (JBIO) in Q1 2026, closing a stake of 53,191 shares — an estimated $821K sold.

9823 Capital first reported a position in JBIO in Q4 2025 and held it in 1 quarter. The position peaked at $821K in Q4 2025. 120 funds tracked by Wall St. Rank hold JBIO as of Q1 2026.

9823 Capital reported no remaining Jade Biosciences position as of Q1 2026 after selling out during the quarter.
9823 Capital sold 53,191 Jade Biosciences shares in Q1 2026, an estimated $821K.
9823 Capital first reported a position in Jade Biosciences in Q4 2025 and held it in 1 quarter.
9823 Capital's Jade Biosciences position peaked at $821K in Q4 2025.
120 funds tracked by Wall St. Rank held Jade Biosciences as of Q1 2026.

Based on 9823 Capital's 13F filing for Q1 2026, filed 15 May 2026.